Loading…
Employees: 131
Size Olema Pharmaceuticals (OLMA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $641M, the 2549th largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.33 on 6 Nov 2026.
Performance Over six months the shares fell 50.8%, against -19.0% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Short interest Short interest is 17.9% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$451,000 | -$490,000 | -$393,000 | -$377,000 | -$1.66M |
| EBITDA | -$221M | -$178M | -$142M | -$105M | -$105M |
| Net income | -$205M | -$162M | -$129M | -$96.7M | -$105M |
| Free cash flow | -$165M | -$147M | -$105M | -$83.7M | -$82.4M |
| Capital expenditure | $221,000 | $0 | $159,000 | $0 | $363,000 |
| Total debt | $3.66M | $4.19M | $1.43M | $2.42M | $2.56M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OLMA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.3% | -4.7% | 10th lowest of 21 |
| 6-month return | -50.8% | -19.0% | lowest of 21 |
| Distance from 52-week high | -79.8% | -35.8% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 1.0× | -4.9% | +6.5% |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 2.9× | 23.2% | +21.9% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | 13.6× | 50.8% | +16.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 2.5× | -2.4% | +6.4% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |